MarketPR
(NASDAQ: PTPI) has ceased substantially all business operations following a General Assignment for the Benefit of Creditors executed on September 30, 2026.
The New York-based company assigned all rights, title, and interest in its assets to PT Liquidation, LLC, under California law, to satisfy creditor claims to the extent possible. The filing, submitted to the U.S.
Securities and Exchange Commission, classifies the assignment as a liquidation event. PT Liquidation, LLC will take possession of the company's assets and administer them according to applicable state law.
As a direct result of this transfer, Petros Pharmaceuticals no longer maintains the ability to continue as a going concern.
Keep reading